Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
SLP 
Simulations Plus Inc (SLP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: SLP (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -45.8% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 488.04M USD | Price to earnings Ratio 60.73 | 1Y Target Price 49.4 |
Price to earnings Ratio 60.73 | 1Y Target Price 49.4 | ||
Volume (30-day avg) 175913 | Beta 0.89 | 52 Weeks Range 23.44 - 51.14 | Updated Date 03/30/2025 |
52 Weeks Range 23.44 - 51.14 | Updated Date 03/30/2025 | ||
Dividends yield (FY) 0.99% | Basic EPS (TTM) 0.4 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-04-01 | When Before Market | Estimate - | Actual - |
Profitability
Profit Margin 11.04% | Operating Margin (TTM) 0.67% |
Management Effectiveness
Return on Assets (TTM) 2.58% | Return on Equity (TTM) 4.6% |
Valuation
Trailing PE 60.73 | Forward PE 21.88 | Enterprise Value 471195246 | Price to Sales(TTM) 6.56 |
Enterprise Value 471195246 | Price to Sales(TTM) 6.56 | ||
Enterprise Value to Revenue 6.33 | Enterprise Value to EBITDA 38.83 | Shares Outstanding 20092400 | Shares Floating 16515781 |
Shares Outstanding 20092400 | Shares Floating 16515781 | ||
Percent Insiders 17.74 | Percent Institutions 80.28 |
Analyst Ratings
Rating 4.71 | Target Price 49 | Buy - | Strong Buy 6 |
Buy - | Strong Buy 6 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Simulations Plus Inc
Company Overview
History and Background
Simulations Plus, Inc. was founded in 1996. It develops and sells simulation and modeling software and consulting services supporting drug discovery, development, and regulatory submissions. The company has grown through organic expansion and acquisitions.
Core Business Areas
- Software Solutions: Development and licensing of simulation and modeling software used in the pharmaceutical, biotechnology, and chemical industries.
- Consulting Services: Provides consulting services to assist clients in using their software and applying modeling and simulation techniques to drug development and other scientific applications.
Leadership and Structure
The company is led by a CEO (Shawn O'Connor), supported by a senior management team overseeing various functional areas. The organizational structure is hierarchical, with departments responsible for software development, sales and marketing, consulting, and finance.
Top Products and Market Share
Key Offerings
- GastroPlus: GastroPlus is a physiologically based pharmacokinetic (PBPK) modeling platform used to simulate drug absorption, distribution, metabolism, and excretion (ADME) in humans and animals. Simulations Plus leads the market for PBPK modeling software. Competitors include Certara (Simcyp Simulator) and Open Systems Pharmacology (PK-Sim). Market share estimations can vary but Simulations Plus is a leading player, estimated around 40-50% of the PBPK market. Revenue is not publicly available but GastroPlus is considered a major revenue driver.
- ADMET Predictor: ADMET Predictor is a machine learning-based software used to predict the absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties of drug candidates. Simulations Plus is also a leading player in this area of the market and has competitors such as Schru00f6dinger, ChemAxon, and Lhasa Limited. Market share estimations can vary but Simulations Plus is a leading player. Revenue is not publicly available.
- DILIsym: DILIsym is a quantitative systems toxicology (QST) modeling platform used to predict drug-induced liver injury (DILI). Competitors include companies that offer similar toxicology prediction tools and services.
Market Dynamics
Industry Overview
The industry involves the use of computer modeling and simulation software in drug discovery, development, and regulatory submissions. This helps reduce development time and costs, as well as predict drug efficacy and safety.
Positioning
Simulations Plus is well-positioned in the industry with its PBPK and ADMET modeling platforms. It has a strong reputation and a loyal customer base. Simulations Plus advantage lies in its comprehensive suite of tools and consulting expertise.
Total Addressable Market (TAM)
The TAM for pharmaceutical simulation and modeling is expected to reach billions of dollars, growing steadily as drug development becomes more complex. Simulations Plus is well-positioned to capture a significant share of this market.
Upturn SWOT Analysis
Strengths
- Strong brand reputation
- Leading technology in PBPK modeling
- Experienced management team
- High customer retention rates
Weaknesses
- Dependence on the pharmaceutical industry
- Relatively small company size
- Potential for slower growth due to industry maturity
Opportunities
- Expansion into new markets (e.g., cosmetics, food)
- Increased adoption of modeling and simulation by regulatory agencies
- Development of new software modules and services
Threats
- Competition from larger companies
- Technological changes
- Economic downturns
Competitors and Market Share
Key Competitors
- CTRA
- DDD
- SCHR
Competitive Landscape
Simulations Plus has advantages in certain segments like PBPK modeling, but larger competitors may have greater resources and broader product offerings.
Major Acquisitions
Cognigen Corporation
- Year: 2015
- Acquisition Price (USD millions): 37.5
- Strategic Rationale: Expanded expertise in quantitative clinical pharmacology and pharmacometrics.
Growth Trajectory and Initiatives
Historical Growth: Simulations Plus has experienced consistent revenue growth over the past years, driven by increasing demand for its software and services.
Future Projections: Analyst estimates for Simulations Plus's future growth are based on industry trends, company performance, and management guidance.
Recent Initiatives: Simulations Plus has undertaken strategic initiatives such as acquisitions and partnerships to expand its product portfolio and market reach.
Summary
Simulations Plus is a strong player in the simulation and modeling software market for the pharmaceutical industry. It has a solid history of growth and a strong reputation, particularly in PBPK modeling. The company is smaller than some of its competitors, and should continue to innovate and expand its product offerings in the growing simulation market.
Similar Companies
- CTRA
- DDD
- SCHR
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Industry reports
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share estimations are approximate and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Simulations Plus Inc
Exchange NASDAQ | Headquaters Lancaster, CA, United States | ||
IPO Launch date 1997-06-18 | CEO - | ||
Sector Healthcare | Industry Health Information Services | Full time employees 243 | Website https://www.simulations-plus.com |
Full time employees 243 | Website https://www.simulations-plus.com | ||
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.